Pediatric Brain Tumors Drug Pipeline Analysis Report 2025

Brain tumors are a diverse group of cancers affecting the brain and spinal cord, with treatment typically beginning with surgery, followed by radiation and chemotherapy as first-line therapy. These tumors are the most common solid malignancy in children, accounting for approximately 25% of all pediatric cancer cases. They are the second-leading cause of tumor-related deaths among children. Despite the standard treatments, there is a significant unmet clinical need for more effective therapies due to the severe side effects and limited efficacy of current options. The growing focus on targeted therapies and immunotherapies is expected to drive significant advancements in the treatment pipeline.

Report Coverage

The Pediatric Brain Tumors Drug Pipeline Insight Report by the publisher gives comprehensive insights into pediatric brain tumors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pediatric brain tumors. The pediatric brain tumors report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pediatric brain tumors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pediatric brain tumors treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pediatric brain tumors.

Pediatric Brain Tumors Drug Pipeline Outlook

Brain tumors are abnormal growths that develop in the brain or spinal cord, often resulting from genetic mutations, environmental factors, or a combination of both. These tumors can form in various parts of the brain, each affecting critical neurological functions, such as motor skills, vision, and cognitive abilities. Depending on their location and type, it can cause a range of symptoms, including headaches, nausea, and seizures, which may require immediate medical attention.

Treatment for pediatric brain tumors typically involves a combination of surgery, radiation therapy, and chemotherapy. Surgery is often the first step to remove as much of the tumor as possible, followed by radiation and chemotherapy to target any remaining cancerous cells. Recent advances have focused on personalized medicine, targeted therapies, and immunotherapy, offering new hope for improving treatment outcomes. Clinical trials are exploring these innovative treatments to minimize side effects and enhance survival rates, providing a more tailored approach for pediatric patients.

Pediatric Brain Tumors Epidemiology

Pediatric brain tumors, accounting for 25% of pediatric cancers and the second-leading cause of tumor-related deaths, present a significant clinical challenge. In the United States, approximately 208,620 adolescents and young adults live with primary brain or spinal cord tumors. In India, brain tumors comprise 8%-12% of childhood cancers, contrasting with 21% in Western countries, highlighting regional differences in incidence rates.

Pediatric Brain Tumors - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pediatric brain tumors drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Immunotherapies
• Gene Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Pediatric Brain Tumors - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total pediatric brain tumors clinical trials.

Pediatric Brain Tumors - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pediatric brain tumors pipeline analysis include small molecules, monoclonal antibodies, immunotherapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pediatric brain tumors.

Pediatric Brain Tumors Clinical Trials Therapeutic Assessment - Competitive Dynamics

The pediatric brain tumors drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pediatric brain tumors clinical trials:

• Neonc Technologies, Inc.
• Pfizer
• Novartis Pharmaceuticals
• Carthera, Photonamic GmbH & Co.KG
• InSightec
• Cellectar Biosciences, Inc.
• Actuate Therapeutics Inc.
• Eli Lilly and Company

Pediatric Brain Tumors Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pediatric brain tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pediatric brain tumors drug candidates.

Drug: Dabrafenib

The Pediatric Long-Term Follow-up and Rollover Study, sponsored by Novartis Pharmaceuticals, aims to evaluate the long-term effects of dabrafenib and/or trametinib in pediatric patients. This Phase 4 study is expected to be completed by May 29, 2026, with around 166 participants. The objective is to assess the ongoing impact of these treatments on conditions like diffuse astrocytoma and oligodendroglioma.

Drug: Palbociclib

The Phase I/II study sponsored by Pfizer aims to evaluate the safety and maximum tolerable dose of palbociclib combined with chemotherapy in pediatric patients with recurrent or refractory solid tumors. The Phase 1 study investigates neuroblastoma activity, while Phase 2 focuses on efficacy in treating Ewing sarcoma. The study, with an estimated 128 participants, is expected to be completed by October 18, 2025.

Drug: NEO100

The objective of the ongoing Phase 1b study sponsored by Neonc Technologies, Inc. is to evaluate the safety, dosing, and delivery of intranasal NEO100 in pediatric patients with high-grade gliomas. Expected to be completed by October 2025, with about 15 participants, the study aims to address the unmet need for more effective therapies in pediatric brain tumor management.

Reasons To Buy This Report

The Pediatric Brain Tumors Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pediatric brain tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pediatric brain tumors collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Pediatric Brain Tumors - Pipeline Insight Report

• Which companies/institutions are leading the pediatric brain tumors drug development?
• What is the efficacy and safety profile of pediatric brain tumors pipeline drugs?
• Which company is leading the pediatric brain tumors pipeline development activities?
• What is the current pediatric brain tumors commercial assessment?
• What are the opportunities and challenges present in the pediatric brain tumors drug pipeline landscape?
• What is the efficacy and safety profile of pediatric brain tumors pipeline drugs?
• Which company is conducting major trials for pediatric brain tumors drugs?
• Which companies/institutions are involved in pediatric brain tumors collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in pediatric brain tumors?

This product will be delivered within 3-5 business days.